MAPK9 and familial dilated cardiomyopathy: Quan Liu and Guang Liang, cooperating with Lu Cai, mainly determined that JNK2 activation enhanced inflammation and DCM, while treatment with a novel curcumin derivative, C66, ameliorated DCM (28–30).